The EuroFlow? strategy to monitor minimal residual disease (MRD) by Next Generation Flow has been focused in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) samples. The BCP-ALL MRD kit, designed following the fully-standardized EuroFlow? 8-color antibody panel, allows measuring MRD and discriminating between normal and malignant BCP cells in 99% of studied BCP-ALL samples. This kit is comprised of two tubes of lyophilized antibodies and additional reagents as follows: Tube 1: 9 antibodies against the surface antigens CD20, CD45, CD81, CD66c, CD123, CD34, CD19, CD10, CD38. Tube 2: 9 antibodies against the surface antigens CD20, CD45, CD81, CD73, CD304, CD34, CD19, CD10, CD38. Compensation Vials: CD34, CD19, CD38, CD45 Bulk Lysis?.
Size
n/a
Concentration
n/a
Applications
Flow Cytometry. Research Use Only. Not for Use in Diagnostic Procedures.